Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Overview

Journal Vaccines (Basel)

Date 2022 Mar 26

PMID 35335037

Authors

Jialu Huang

Yubo Ding

Jingwei Yao

Minghui Zhang

Yu Zhang

Zhuoyi Xie

Jianhong Zuo

Affiliations

Soon will be listed here.

Abstract

COVID-19 is still prevalent around the globe. Although some SARS-CoV-2 vaccines have been distributed to the population, the shortcomings of vaccines and the continuous emergence of SARS-CoV-2 mutant virus strains are a cause for concern. Thus, it is vital to continue to improve vaccines and vaccine delivery methods. One option is nasal vaccination, which is more convenient than injections and does not require a syringe. Additionally, stronger mucosal immunity is produced under nasal vaccination. The easy accessibility of the intranasal route is more advantageous than injection in the context of the COVID-19 pandemic. Nanoparticles have been proven to be suitable delivery vehicles and adjuvants, and different NPs have different advantages. The shortcomings of the SARS-CoV-2 vaccine may be compensated by selecting or modifying different nanoparticles. It travels along the digestive tract to the intestine, where it is presented by GALT, tissue-resident immune cells, and gastrointestinal lymph nodes. Nasal nanovaccines are easy to use, safe, multifunctional, and can be distributed quickly, demonstrating strong prospects as a vaccination method for SARS-CoV-2, SARS-CoV-2 variants, or SARS-CoV-n.

Citing Articles

Characterization of Spray-Dried Powders Using a Coated Alberta Idealized Nasal Inlet.

Duong K, Aisenstat M, Chen J, Murphy B, Tavernini S, Wang H J Aerosol Med Pulm Drug Deliv. 2025; 38(1):1-12.

PMID: 39804033 PMC: 11839532. DOI: 10.1089/jamp.2024.0029.

Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis.

Zhang X, Guo M, Huang Z, Huang Y, Wu C, Pan X Infect Med (Beijing). 2023; 1(2):103-112.

PMID: 38013718 PMC: 9233748. DOI: 10.1016/j.imj.2022.06.005.

Role of Immunoglobulin A in COVID-19 and Influenza Infections.

Tyagi R, Basu S, Dhar A, Gupta S, Gupta S, Jaiswal R Vaccines (Basel). 2023; 11(11).

PMID: 38005979 PMC: 10675305. DOI: 10.3390/vaccines11111647.

Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.

Mufamadi M, Ngoepe M, Nobela O, Maluleke N, Phorah B, Methula B Biomed Res Int. 2023; 2023:4588659.

PMID: 37181817 PMC: 10175023. DOI: 10.1155/2023/4588659.

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic.

Chakraborty C, Bhattacharya M, Dhama K Vaccines (Basel). 2023; 11(3).

PMID: 36992266 PMC: 10054865. DOI: 10.3390/vaccines11030682.

References

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

Awadasseid A, Wu Y, Tanaka Y, Zhang W . Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021; 17(1):8-19. PMC: 7757035. DOI: 10.7150/ijbs.52569. View

Cid R, Bolivar J . Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules. 2021; 11(8). PMC: 8394948. DOI: 10.3390/biom11081072. View

Rodolfo C, Eusebio D, Ventura C, Nunes R, Florindo H, Costa D . Design of Experiments to Achieve an Efficient Chitosan-Based DNA Vaccine Delivery System. Pharmaceutics. 2021; 13(9). PMC: 8471690. DOI: 10.3390/pharmaceutics13091369. View

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

Lu J, Lu G, Tan S, Xia J, Xiong H, Yu X . A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020; 30(10):936-939. PMC: 7429369. DOI: 10.1038/s41422-020-00392-7. View

Tillett R, Sevinsky J, Hartley P, Kerwin H, Crawford N, Gorzalski A . Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; 21(1):52-58. PMC: 7550103. DOI: 10.1016/S1473-3099(20)30764-7. View

Cordeiro A, Alonso M, Fuente M . Nanoengineering of vaccines using natural polysaccharides. Biotechnol Adv. 2015; 33(6 Pt 3):1279-93. PMC: 7127432. DOI: 10.1016/j.biotechadv.2015.05.010. View

Dror A, Eisenbach N, Taiber S, Morozov N, Mizrachi M, Zigron A . Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020; 35(8):775-779. PMC: 8851308. DOI: 10.1007/s10654-020-00671-y. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

Sun W, Leist S, McCroskery S, Liu Y, Slamanig S, Oliva J . Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62:103132. PMC: 7679520. DOI: 10.1016/j.ebiom.2020.103132. View

12.

Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene W . mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife. 2021; 10. PMC: 8545397. DOI: 10.7554/eLife.72619. View

13.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

14.

Liu Z, Cao S, Liu M, Kang W, Xia J . Self-Assembled Multienzyme Nanostructures on Synthetic Protein Scaffolds. ACS Nano. 2019; 13(10):11343-11352. DOI: 10.1021/acsnano.9b04554. View

15.

Zuo J, Wen M, Lei M, Xiao X, Liu Z . PLGA-Der p1 Vaccine Inhibited Tumor Growth in a Murine Model of Lung Cancer. Arch Med Res. 2015; . DOI: 10.1016/j.arcmed.2015.12.005. View

16.

Luo Q, Hou C, Bai Y, Wang R, Liu J . Protein Assembly: Versatile Approaches to Construct Highly Ordered Nanostructures. Chem Rev. 2016; 116(22):13571-13632. DOI: 10.1021/acs.chemrev.6b00228. View

17.

Tan Q, He L, Meng X, Wang W, Pan H, Yin W . Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. J Nanobiotechnology. 2021; 19(1):173. PMC: 8190731. DOI: 10.1186/s12951-021-00926-0. View

18.

Allison A, Gregoriadis G . Liposomes as immunological adjuvants. Nature. 1974; 252(5480):252. DOI: 10.1038/252252a0. View

19.

Srivastava M, Hall D, Omoru O, Gill H, Smith S, Janga S . Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components. Microorganisms. 2021; 9(9). PMC: 8464733. DOI: 10.3390/microorganisms9091794. View

20.

Motamedi H, Mahdizade Ari M, Dashtbin S, Fathollahi M, Hossainpour H, Alvandi A . An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Int Immunopharmacol. 2021; 96:107763. PMC: 8101866. DOI: 10.1016/j.intimp.2021.107763. View